Josh Ofman

Josh Ofman, M.D., is the president of GRAIL, Inc., a biotechnology company focused on early cancer detection; he commented on the transformative potential of the Galleri blood test in cancer screening, highlighting its ability to detect new cancers at early stages and guide efficient diagnostic workups.